Theranos is just one example of how poor governance can lead to disaster – including the prison sentences of its founder-entrepreneur and her partner. While this is an exceptional case of governance failure, it is regrettably not an exception. American tech entrepreneurs are characteristically negative about the virtues of governance. The ouster of Steve Jobs from Apple in 1985 after a power struggle with the board and CEO, and Elon Musk's antics at Twitter are just two examples that attest to this.

https://knowledge.insead.edu/entrepreneurship/what-all-tech-start-ups-need-succeed

#insead

'Many people have this idea that you need to have a genius leader or to be a startup to innovate. It's not true,' said Bensaou, whose book Built to Innovate demystifies innovation and shows organisations how they can develop an innovation engine. Even traditional or centuries-old companies are able to innovate, he said. 'This is innovation driven by everyone in the organisation, not just the genius leader or R&D capability.' The tools of innovation To get there, companies should first recognise that every employee has the potential to generate ideas and, importantly, give them the permission to do so.

https://knowledge.insead.edu/leadership-organisations/really-simple-steps-creating-innovation-engine

#insead

Chess grandmaster  Garry Kasparov wrote in Deep Thinking that a (weak) human working with a machine, with a strong process to work together, can produce better outcomes than when AI and humans work alone, said Evgeniou. According to Kasparov, building a better process at the human-machine interface requires humans to be informed. In other words, we need to know the technology to understand its potential, limits and challenges. Unpacking ChatGPT ChatGPT is a specific product in a class of technologies known as large language models (LLMs) – an application area of machine learning (ML), itself at the heart of modern AI.

https://knowledge.insead.edu/strategy/how-will-chatgpt-shape-business-society-and-employment

#insead

While many sectors were dealt a punishing blow during the pandemic, Covid-19 ushered in a boom in the biotech industry. Biotech start-ups raised US$34 billion globally in 2021, double the figure in 2020, and the worldwide market size is expected to grow nearly 14 percent per year from 2022 to 2030. But though the industry is flourishing, many smaller firms could remain one-trick ponies that only produce a single product, while others may never bring an asset to market. Indeed, around 90 percent of drug candidates fail to make it to the commercialisation stage.

https://knowledge.insead.edu/operations/how-biotech-firms-can-improve-cross-functional-collaboration

#insead